Trials / Enrolling By Invitation
Enrolling By InvitationNCT07292571
Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107
SPECT/CT Imaging of Different Types of HER2 Expression in Breast Cancer Using Technetium-99m-labelled Affibody [99mTc]Tc -ZHER2:4107
- Status
- Enrolling By Invitation
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences · Academic / Other
- Sex
- Female
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The study should evaluate the \[99mTc\]Tc -ZHER2:4107 accumulation in primary tumour of breast cancer patients with different HER2 expression
Detailed description
To determine different HER2 expression in primary breast cancer patients before any system or local treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Injection of [99mTc]Tc-ZHER2:4107, SPECT/CT | One single injection of \[99mTc\]Tc-ZHER2:4107, followed by SPECT/CT imaging 2 hours after injection |
Timeline
- Start date
- 2025-10-20
- Primary completion
- 2026-03-30
- Completion
- 2026-03-30
- First posted
- 2025-12-18
- Last updated
- 2025-12-18
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT07292571. Inclusion in this directory is not an endorsement.